Treatment with ISC-hpNSC, an investigational stem cell therapy for Parkinson’s disease, was safe and well-tolerated over at least two years in an early clinical trial in 12 patients. Results from the small trial, which treated patients at low, medium and high doses, also indicate that the therapy eased Parkinson’s-related symptoms…

A second group of Parkinson’s patients in a Phase 1 clinical trial have received International Stem Cell Corporation’s neural stem cell therapy. The main goal of the trial (NCT02452723) at Royal Melbourne Hospital is to see whether ISCO’s stem cell transplants are safe, and patients can tolerate them. All patients…

Patients with moderate-to-severe Parkinson’s disease who received human neural stem cells in their brain as part of a Phase 1 trial are performing better at six months than they were at the start of the study. Also, all patients are meeting the trial’s primary goal of safety, according to a…

Stem cell therapy, which many people living with Parkinson’s disease have long pinned hope on as a potential treatment or even a cure, is finally advancing to clinical trial stage. The recent announcement of a Phase 1/2a clinical trial involving transplantation of stem cells into the first human subjects is…

International Stem Cell Corporation announced that its subsidiary, Cyto Therapeutics, has been given regulatory permission to start a Phase 1/2a dose escalation clinical trial of its neural stem cells (ISC-hpNSC) in the treatment of Parkinson’s disease (PD). Clearance for the trial came the Therapeutics Goods Administration (TGA) of Australia. The trial will test…

According to the Mayo Clinic, current treatments are often unable to address the medical needs of Parkinson’s patients, since clinicians only have access to drugs or devices that manage symptoms. Nevertheless, several developments in immunology, cell biology and other fields have advanced the potential for regenerative medicine to make an impact on treating Parkinson’s disease patients in…